Larimar Therapeutics Inc LRMR:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 4:25 PM EDT
7.93quote price arrow up+0.04 (+0.51%)
Volume
9,998
Close
7.89quote price arrow up+0.62 (+8.53%)
Volume
2,585,912
52 week range
2.18 - 13.68
Loading...
  • Open8.05
  • Day High8.68
  • Day Low7.45
  • Prev Close7.27
  • 52 Week High13.68
  • 52 Week High Date02/15/24
  • 52 Week Low2.18
  • 52 Week Low Date11/10/23

Key Stats

  • Market Cap503.398M
  • Shares Out63.80M
  • 10 Day Average Volume0.32M
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • YTD % Change73.41

KEY STATS

  • Open8.05
  • Day High8.68
  • Day Low7.45
  • Prev Close7.27
  • 52 Week High13.68
  • 52 Week High Date02/15/24
  • 52 Week Low2.18
  • 52 Week Low Date11/10/23
  • Market Cap503.398M
  • Shares Out63.80M
  • 10 Day Average Volume0.32M
  • Dividend-
  • Dividend Yield-
  • Beta0.86
  • YTD % Change73.41

RATIOS/PROFITABILITY

  • EPS (TTM)-0.97
  • P/E (TTM)-8.16
  • Fwd P/E (NTM)-6.41
  • EBITDA (TTM)-50.474M
  • ROE (TTM)-26.75%
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date08/08/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Larimar Therapeutics Inc

 

Profile

MORE
Larimar Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. The Company’s lead product candidate, nomlabofusp, is a subcutaneously administered, recombinant fusion protein intended to deliver tissue frataxin (FXN), an essential protein, to the mitochondria of patients with Friedreich's ataxia (FA). FA...
Joseph Truitt
Independent Chairman of the Board
Carole Ben-Maimon M.D.
President, Chief Executive Officer, Director
Michael Celano
Chief Financial Officer, Company Secretary
Address
THREE BALA PLAZA EAST. SUITE 506
Bala Cynwyd, PA
19004
United States

Top Peers

SYMBOLLASTCHG%CHG
CRBP
Corbus Pharmaceuticals Holdings Inc
45.20-3.35-6.90%
APLT
Applied Therapeutics Inc
4.24+0.04+0.95%
NKTX
Nkarta Inc
6.53-0.20-2.97%
FULC
Fulcrum Therapeutics Inc
7.64-0.06-0.78%
BMEA
Biomea Fusion Inc
11.58-1.04-8.24%